Source-grounded facts extracted from Harmony Biosciences Holdings, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Harmony Biosciences Holdings, Inc. reported the quarter ended March 31, 2026 results: revenue $215.4 million. Guidance reaffirmed.
“BIOSCIENCES REPORTS Q1 FINANCIAL RESULTS AND CONFIRMS 2026 NET REVENUE GUIDANCE OF OVER $1 BILLION; REINFORCES 2026 STRATEGIC PRIORITIES WAKIX® Net Revenue Grew 17% to $215.4 Million for First Quarter 2026; On Track for Full Year 2026 Net Revenues over $1 Billion Continue to Vigorously Protect WAKIX IP into 2030; Filed Suit Against AET Pharma/Sandoz”
Ron Philip was appointed as Class III director at Harmony Biosciences Holdings, Inc..
“Effective April 2, 2025, the Board of Directors (the “Board”) of Harmony Biosciences Holdings, Inc. (the “Company”) appointed Ron Philip, age 51, as a Class III director, filling the previously announced vacancy in the Board created by the resignation of Jack Bech Nielsen effective June 27, 2024.”
Jeffrey Dierks departed as Chief Commercial Officer at Harmony Biosciences Holdings, Inc..
“Jeffrey Dierks will be departing from the Company as its Chief Commercial Officer, effective as of March 31, 2025 (the “Effective Date”), for personal reasons.”
Jack Bech Nielsen resigned as Director at Harmony Biosciences Holdings, Inc..
“On June 27, 2024, Jack Bech Nielsen notified the Board of Directors (the “Board”) of Harmony Biosciences Holdings, Inc. (the “Company”) that he is resigning from the Board effective immediately, due to health reasons.”
Kumar Budur was appointed as Executive Vice President and Chief Medical & Scientific Officer at Harmony Biosciences Holdings, Inc..
“appointed Kumar Budur, M.D., M.S., the Company’s Chief Medical Officer, to the title of Executive Vice President and Chief Medical & Scientific Officer (the “Appointment”), effective on May 1, 2024”
Harmony Biosciences Holdings, Inc. reported Q1 2024 results: revenue WAKIX Net Revenue of $154.6 Million, net income GAAP net income for the quarter ended March 31, 2024, was $38.3 million, EPS $0.67 per diluted share. Guidance reaffirmed.
“ADVANCES PITOLISANT FRANCHISE TO EXTEND REVENUE POTENTIAL BEYOND 2040; STRENGHTENS SLEEP/WAKE LEADERSHIP AND DIVERSIFIES INTO RARE EPILEPSY WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia Planned for Second Half 2024 On Track Toward”
Harmony Biosciences Holdings, Inc. reported financial results for the quarter and year ended December 31, 2023.
“On February 22, 2024, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023.”
Harmony Biosciences Holdings, Inc. reported 2024 results: revenue $700 million to $720 million. Guidance initiated.
“Expect full year 2024 net product revenue of $700 million to $720 million”
Harmony Biosciences Holdings, Inc. reported the full year ended December 31, 2023 results: revenue approximately $582 million. Guidance raised.
“Preliminary, unaudited net product revenue for the full year ended December 31, 2023, was approximately $582 million, compared to $437.9 million for the same period in 2022, representing ~33% growth”
Harmony Biosciences Holdings, Inc. reported the fourth quarter ended December 31, 2023 results: revenue approximately $168 million. Guidance raised.
“Preliminary, unaudited net product revenue for the quarter ended December 31, 2023, was approximately $168 million, compared to $128.3 million for the same period in 2022, representing ~31% growth”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.